JPT/A2T-Beta-Amyloid (1-42); HFIP treated (0.5mg)/SP-Ab-25_0.5/

A2T-Beta-Amyloid(1-42);HFIPtreated(0.5mg)

ProductCode:SP-Ab-25_0.5

VariantofhumanAmyloidbetaA4protein,whereAla2isreplacedbyaThreonine(Thr)(Swiss-ProtID:P05067).HFIPtreatmentisperformedtodisruptβ-sheetandotherunwantedsecondarystructures.
AminoAcidSequence:DTEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
ProteinName:Amyloidbeta(A4)(alternativenames:Abeta,Betaamyloid,APP)
Amount:1vial(0.5mg)
Purity:>90%(HPLC-MS)
DeliveryFormat:Freezedriedinplasticvials5
Application(s):Invitrostaining,Bindingexperiments
Indication(s)/Topic(s):Neurodegenerativedisease,Alzheimer"sdisease
DeliveryTime:2-5days

JPT"sSingleCatalogPeptides
JPTPeptideTechnologieshassubstantial,long-standingexpertiseinprovidingpeptides,peptidomimetics,andproteinstotheglobalscientificcommunity.Ourhighlyskilledandcommittedscientificstaffensuresthatthemostappropriatemethodsandtechniquesareselectedforeverysynthesisproject.AllofJPT"scatalogpeptidesareprovidedwithHPLC-MSanalysestoconfirmtheidentityanddemonstratethehighqualityofourpeptides.

BenefitsofJPT"sSingleCatalogPeptides
-WholeproductionperformedinaregulatedEuropeanenvironmentaccordingtoDINENISO9001:2015&GCLPstandards;auditswelcome!
-Synthesisprotocolsdesignedtoavoidtoxiccontaminantsandsideproducts
-ProvisionoffreezedriedaliquotsforenhancedstABIlity
-Proventrackrecordforapplicationsinclinicalstudies

A2T-Beta-Amyloid(1-42);HFIPtreated(0.5mg)

SelectedReferences
"CompetitiveMirrorImagePhageDisplayDerivedPeptideModulatesAmyloidBetaAggregationandToxicity"
Rudolphetal.,PLoSOne. (2016)-PMID:26840229
"InhibitionoftheCardiacNa+Channelα-subunitNav1.5byPropofolandDexmedetomidine"
Stoetzeretal.,NaunynSchmiedebergsArchPharmacol.-PMID:26667357
"Aβ-42loweringAgentsFromtheMarine-DerivedFungusDichotomomycesCejpii"
Harmsetal.,Steroids.(2015)-PMID:26440473
"η-SecretaseProcessingofAPPInhibitsNeuronalActivityintheHippocampus"
Willemetal.,Nature(2015)-PMID:26322584
"HybridizationofanAβ-specificAntibodyFragmentwithAminopyrazole-basedβSheetLigandsDisplaysStrikingEnhancementofTargetAffinity"
Hellmertetal.,Org.Biomol.Chem.(2015)-PMID:25613910

ApplicationNote
"SyntheticAmyloidBetaPeptidesAidAlzheimerInvestigation"
Broersenetal.,ApplicationNote(2013)(fulltext)

Testimonial
“OurgroupfocusesontheinvitrostudyofriskfactorsinAlzheimer’sdiseaseand,asweexperiencedthatthein-houseexpressionandproductionoftheamyloidbetapeptideisnotoriouslydifficult,wearecontinuouslydependentonahighqualitysupplyofalargevarietyofthesepeptidesfromcommercialsource.WestartedourcollaborationwithJPTwiththeirrequesttotestarangeoftheirpeptidesfortheabilitytoproducetoxicoligomersandfibrillarnetworksandwereimpressedbytherapidsupplyofaverywiderangeofhighpuritypeptideswithexcellentfibrilformingpropertiesandtoxicityprofiles.JPThasshownrealvaluableknow-howandexperienceinthefieldofpeptidesynthesisbytheirabilitytogeneratehighqualitypreparationsofamyloidbetapeptidevariantswhichareknownfortheirdifficultytohandle.”
KerensaBroersen,AssistantProf.,NanobiophysicsGroup,UniversityofTwente,Enschede,TheNetherlands